Premium
A clinical double‐blind trial comparing amorolfine cream 0·5% (RO‐14‐4767) with bifonazole cream 1% in the treatment of dermatomycoses
Author(s) -
DEL PALACIOHERNANZ A.,
LÓPEZGÓMEZ S.,
MORENOPALANCAR P.,
GONZÁLEZLASTRA F.
Publication year - 1989
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1989.tb00912.x
Subject(s) - bifonazole , medicine , dermatology , double blind , clinical trial , antifungal , pathology , placebo , alternative medicine
Summary In a double‐blind parallel study, 40 patients with dermatomycoses (one cutaneous candidosis and, 39 dermatophyte infections) were treated topically with amorolfine (RO‐14‐4767) cream (0·5%), a new antifungal compound, or with bifonazole cream (1%). The treatment was applied once daily and was continued until 1 week after resolution of the symptoms, the maximum duration of treatment was limited to 6 weeks. Assessment of results was based on both clinical and mycological parameters. The percentages of amorolfine‐and bifonazole‐treated patients who were clinically and mycologically cured were 83·33% and 78·95% respectively. Two patients treated with amorolfine and one patient treated with bifonazole were withdrawn from the trial because of side‐effects. There was no significant difference between the two creams in clinical and mycological cure rates and tolerance.